Unauthorized Use of Content on this Site: The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB)—including, but not limited to, those available through the PAAB Forum, the PAAB website, and any PAAB correspondence—are specifically intended to assist individuals navigating the PAAB preclearance system. Repurposing or reproducing this content, or using it for model training or any related purposes, is strictly prohibited without the express prior written consent of PAAB. This includes, but is not limited to, the use of such materials in automated systems, machine learning models, or artificial intelligence applications.
446 - Can you confirm whether Code sections 2.10.1 and 2.10.2 are mutually exclusive? For example, could an abbreviated indication appear with the first marketing claim in an APS, with the verbatim indication appearing elsewhere in the APS?
-
2.10.1 and 2.10.2 are not mutually exclusive. A statement conveying all boundaries of patient selection must be presented among (or prior to) the first set of marketing benefit claims in the APS. This statement may be the verbatim indication (thus satisfying both 2.10.1 and 2.10.2), or it may be some other statement identifying all boundaries of patient selection in an alternate format (e.g. “Only use drug X in patients who…”). In the latter case, the verbatim indication must still appear somewhere in the piece. Additionally, use of the statement “indicated for” should be restricted to the verbatim indication. Refer to the PAAB guidance document “Guidance on indication placement in advertising” for additional information.
